How many insider trades does FilingIQ track for RIGL?

FilingIQ tracks 151 Form 4 insider transactions for RIGL (RIGEL PHARMACEUTICALS INC), covering filings from Jan 26, 2015 onwards. 8 of those were filed in the last 90 days.

Are RIGL insiders net buyers or net sellers?

Across the full Form 4 history for RIGL, 7 transactions (5%) were open-market purchases and 28 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RIGL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RIGL in?

RIGEL PHARMACEUTICALS INC (RIGL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $627.13M.

RIGL insider trading

NasdaqGS Healthcare

RIGEL PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

151

Last 90 days

Buys / sells

5% / 19%

Market cap

$627.13M

About RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Company website: www.rigel.com

RIGL insider activity at a glance

FilingIQ has scored 151 insider transactions for RIGL since Jan 26, 2015. The most recent filing in our index is dated Feb 20, 2026.

Across the full history, 7 open-market purchases and 28 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RIGL insider trades is 61.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RIGL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for RIGL?: FilingIQ tracks 151 Form 4 insider transactions for RIGL (RIGEL PHARMACEUTICALS INC), covering filings from Jan 26, 2015 onwards. 8 of those were filed in the last 90 days.
Are RIGL insiders net buyers or net sellers?: Across the full Form 4 history for RIGL, 7 transactions (5%) were open-market purchases and 28 (19%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RIGL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RIGL in?: RIGEL PHARMACEUTICALS INC (RIGL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $627.13M.

Methodology & sources

Every RIGL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.